Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 25383971 | HLA-DRB1*04 | enteric fever | NA | NA | rs7765379 | unclassified | |
| imputation-based fine-mapping across the extended mhc region showed that the classical hla-drb1*04:05 allele (or = 0.14, p = 2.60 x 10(-11)) could entirely explain the association at rs7765379, thus implicating hla-drb1 as a major contributor to resistance against enteric fever, presumably through antigen presentation. | |||||||
| 25483343 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | drug side effects | NA | NA | NA | unclassified | |
| drug side effects show stronger associations to genetic variants, including human leukocyte antigen loci with carbamazepine-induced dermatologic outcome and mc4r with atypical antipsychotic weight gain. | |||||||
| 32233158 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | drug side effects | NA | NA | NA | unclassified | |
| human leukocyte antigen (hla) typing is important for transplant patients to prevent a severe mismatch reaction, and the result can also support the diagnosis of various disease or prediction of drug side effects. | |||||||
| 25517089 | HLA-DR3 (BROAD ANTIGEN) | tick infestations | NA | NA | NA | unclassified | |
| serial tick infestations with pathogen-free ixodes scapularis ticks were used to tick-bite sensitize hla dr3 tg mice. | |||||||
| 25517089 | HLA-DR (HLA-DR) | tickborne disease | NA | NA | NA | unclassified | |
| this study provides the first proof-of-concept for using hla dr tg "humanized" mice for studying the potential tick protective effects of immunoinformatic- or otherwise-derived tick salivary components as tickborne disease vaccines. | |||||||
| 27517505 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | vascularized composite allotransplantation | NA | NA | NA | unclassified | |
| although dsa characteristics, human leukocyte antigen class specificity, mean fluorescence intensity and immunoglobulin g subclasses, and their impact on the graft are quite well studied in solid organ transplants, very little information is known about their impact on vascularized composite allotransplantation (vca). | |||||||
| 29150964 | HLA (HLA) | vascularized composite allotransplantation | NA | NA | NA | unclassified | |
| de novo donor-specific hla antibodies after combined intestinal and vascularized composite allotransplantation - a retrospective study. | |||||||
| 25791070 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | cerebral palsy | NA | NA | NA | only_studied | |
| during a post-registration clinical investigation, the safety and efficacy of intravenous infusion of allogeneic human leukocyte antigen (hla)-unmatched umbilical cord blood (ucb) cells were studied in 80 pediatric patients with cerebral palsy and associated neurological complications. | |||||||
| 25854937 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | high grade squamous intraepithelial lesions | NA | NA | NA | unclassified | |
| this method was then applied to a longitudinal study of human leukocyte antigen (hla) genotype and risk of cervical high grade squamous intraepithelial lesions (hsil) among hiv-infected and hiv-uninfected women. | |||||||
| 25977825 | HLA MISMATCHED (HLA-MISMATCHED) | myeloid sarcoma | NA | NA | NA | unclassified | |
| these cases suggest that restoration of the immune system after withdrawal of immunosuppressive therapy and allograft nephrectomy may be sufficient to control hla-mismatched donor-derived myeloid sarcoma without systemic involvement. | |||||||
Copyright 2024